Recombinant Human KNG1 (C-6His)

Recombinant Human KNG1 (C-6His)

Size1:10μg price1:$168
Size2:50μg price2:$465
Size3:500μg price3:$2350
SKU: PHH1047 Category: Target Proteins Tags: ,

Datasheet

Name

Recombinant Human KNG1 (C-6His)

Purity

Greater than 95% as determined by reducing SDS-PAGE

Endotoxin level

<1 EU/µg as determined by LAL test.

Construction

Recombinant Human Kininogen-1 is produced by our Mammalian expression system and the target gene encoding Gln19-Ser427 is expressed with a 6His tag at the C-terminus.

Accession #

P01042-2

Host

Human Cells

Species

Human

Predicted Molecular Mass

46.89 KDa

Buffer

Lyophilized from a 0.2 μm filtered solution of 20mM Hac-NaAC, 150mM NaCl, pH 4.0.

Form

Lyophilized

Shipping

The product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.

Stability&Storage

Store at ≤-70°C, stable for 6 months after receipt.Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.

Reconstitution

Always centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

 

 

 

Alternative Names

Kininogen-1; lpha-2-Thiol Proteinase Inhibitor; Fitzgerald Factor; High Molecular Weight Kininogen; HMWK; Williams-Fitzgerald-Flaujeac Factor; KNG1; BDK; KNG

 

Background

Kininogen-1 is a secreted protein which contains three cystatin domains. There are two alternatively spliced forms, designated as the high molecular weight (HMW) and low MW (LMW) forms. Kininogen-1 plays a critical role in blood coagulation and inflammatory response. Kininogens are inhibitors of thiol proteases. Kininogen-1 participates in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII, also inhibits the thrombin- and plasmin-induced aggregation of thrombocytes. The active peptide bradykinin that is released from Kininogen-1 shows a variety of physiological effects: influence in smooth muscle contraction, induction of hypotension, natriuresis and diuresis, decrease in blood glucose level. It is a mediator of inflammation and causes increase in vascular permeability, stimulation of nociceptors release of other mediators of inflammation. It has a cardioprotective effect. LMW-kininogen inhibits the aggregation of thrombocytes and doesn’t involved in blood clotting.

 

Note

For Research Use Only , Not for Diagnostic Use.